Talphera price target raised to $6 from $5 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Talphera to $6 from $5 and keeps a Buy rating on the shares. The company’s financing arrangements are a crucial step to extend its cash runway, and thus removes any financial overhang ahead of Niyad’s potential FDA approval, the analyst tells investors in a research note.